U.S. Markets close in 2 hrs 47 mins

Depomed acquisition makes strategic sense, says JMP Securities

After Depomed announced that it had acquired migraine treatment CAMBIA, JMP Securities thinks that the deal leverages the company’s established neurology-focused sales organization. The firm raised its price target on the stock to $11 from $10 and reiterates an Outperform rating on the shares.